---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-196475"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:08:28.413283+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma Q2 Portfolio Receipts $608M (+12% YoY); raises FY 2024 guidance to $2.7-2.775B

## Summary
- Royalty Receipts grew 11% to $605M, driven by cystic fibrosis franchise, Trelegy (+32%), Tremfya (+34%), and Evrysdi (+91%).
- Raised FY 2024 Portfolio Receipts guidance: $2,700M-$2,775M (previous $2,600M-$2,700M), implying 9-12% Royalty Receipts growth.
- Capital deployed ~$2B YTD including $905M for Voranigo (approved Aug 6) and $575M expanded Cytokinetics collaboration.
- Issued $1.5B senior notes at 5.5% in June; total debt $7.8B at 3.1% avg cost; repurchased 4M shares for $115M YTD.
- Trodelvy Phase 3 TROPiCS-04 failed survival endpoint; BioCryst discontinued BCX10013 – potential portfolio headwinds.

## SEC filing metadata
- accession: 0001193125-24-196475
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312524196475/0001193125-24-196475-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312524196475/d857022d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-196475
- JSON: https://secwatch.observer/filing/0001193125-24-196475.json
- Plain text: https://secwatch.observer/filing/0001193125-24-196475.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.